iShares Neuroscience and Healthcare ETF (IBRN) Holdings
IBRN holdings summary
as of Oct 24, 2026- Holdings
- 68 positions listed
- Top 10 weight
- 42.1% of net assets
- Effective holdings
- 34 equal-weight equivalent
- Largest holding
- BIIB 5.86% Biogen Inc.
- Annual turnover
- 61.7% of the portfolio traded
All IBRN holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | BIIB | Biogen Inc. | Healthcare | 5.86% | $371,937.43 | $34.37B | 41.3 |
| 2 | ALKS | Alkermes plc | Healthcare | 4.66% | $296,166.63 | $6.92B | 108.5 |
| 3 | EWTX | Edgewise Therapeutics, Inc. | Healthcare | 4.55% | $289,110.36 | $4.04B | — |
| 4 | NBIX | Neurocrine Biosciences, Inc. | Healthcare | 4.47% | $283,921.36 | $13.79B | 19.9 |
| 5 | PTCT | PTC Therapeutics, Inc. | Healthcare | 4.25% | $269,910.43 | $4.94B | — |
| 6 | ARGX | argenx SE | Healthcare | 4.02% | $255,188.16 | $51.51B | 31.2 |
| 7 | SRRK | Scholar Rock Holding Corporation | Healthcare | 3.65% | $231,567.74 | $4.86B | — |
| 8 | ACAD | ACADIA Pharmaceuticals Inc. | Healthcare | 3.58% | $227,401.30 | $3.29B | 8.6 |
| 9 | DNTH | Dianthus Therapeutics, Inc. | Healthcare | 3.58% | $227,394.95 | $4.03B | — |
| 10 | SUPN | Supernus Pharmaceuticals, Inc. | Healthcare | 3.45% | $218,941.39 | $2.21B | — |
| 11 | 326030 | Sk Biopharmaceuticals Co Ltd | Healthcare | 3.43% | $217,931.54 | — | — |
| 12 | PRAX | Praxis Precision Medicines, Inc. | Healthcare | 3.41% | $216,597.77 | $6.75B | — |
| 13 | HLUN-B | H Lundbeck A/S | Healthcare | 3.26% | $206,994.63 | — | — |
| 14 | DYN | Dyne Therapeutics, Inc. | Healthcare | 3.09% | $196,305.42 | $2.66B | — |
| 15 | XENE | Xenon Pharmaceuticals Inc. | Healthcare | 3.06% | $194,482.61 | $3.24B | — |
| 16 | AXGN | AxoGen, Inc. | Healthcare | 2.98% | $189,382.53 | $2.03B | — |
| 17 | BHVN | Biohaven Ltd. | Healthcare | 2.88% | $183,139.22 | $1.63B | — |
| 18 | SRPT | Sarepta Therapeutics, Inc. | Healthcare | 2.84% | $180,338.30 | $1.81B | — |
| 19 | NEU | Neuren Pharmaceuticals Ltd | Healthcare | 2.37% | $150,303.09 | — | — |
| 20 | BIOA-B | BioArctic AB (publ) | Healthcare | 2.04% | $129,337.51 | — | — |
| 21 | TSHA | Taysha Gene Therapies, Inc. | Healthcare | 1.59% | $100,959.98 | $1.18B | — |
| 22 | LBRX | LB Pharmaceuticals Inc | Healthcare | 1.54% | $97,638.26 | $1.19B | 367.4 |
| 23 | IDIA | Idorsia Ltd | Healthcare | 1.42% | $89,927.80 | — | — |
| 24 | 4588 | Oncolys Biopharma Inc | Healthcare | 1.34% | $85,062.72 | — | — |
| 25 | IART | Integra LifeSciences Holdings Corporation | Healthcare | 1.27% | $80,604.12 | $1.03B | — |
| 26 | RUBICON | Rubicon Research Limited | Healthcare | 1.24% | $78,863.87 | — | — |
| 27 | ANRO | Alto Neuroscience, Inc. | Healthcare | 1.19% | $75,688.23 | $861.0M | — |
| 28 | RAPP | Rapport Therapeutics, Inc. | Healthcare | 1.17% | $74,443.38 | $1.32B | — |
| 29 | CBLL | CeriBell, Inc | Healthcare | 1.13% | $71,483.68 | $961.0M | — |
| 30 | MEDCL | Medincell SA | Healthcare | 1.09% | $69,082.89 | — | — |
| 31 | APMD | Apnimed, Inc. | Healthcare | 1.07% | $67,907.91 | $739.4M | 2.5 |
| 32 | DYVOX | Dynavox Group | Healthcare | 1.04% | $66,174.01 | — | — |
| 33 | ANNX | Annexon, Inc. | Healthcare | 0.95% | $60,095.83 | $646.5M | — |
| 34 | SLDB | Solid Biosciences Inc. | Healthcare | 0.81% | $51,223.09 | $593.0M | — |
| 35 | BWAY | BrainsWay Ltd. | Healthcare | 0.65% | $41,073.74 | $460.5M | 49.7 |
| 36 | OVID | Ovid Therapeutics Inc. | Healthcare | 0.64% | $40,495.77 | $419.9M | — |
| 37 | DRUG | Bright Minds Biosciences Inc. | Healthcare | 0.63% | $40,286.18 | $506.0M | — |
| 38 | PRTA | Prothena Corporation plc | Healthcare | 0.59% | $37,663.10 | $428.7M | — |
| 39 | DSGN | Design Therapeutics, Inc. | Healthcare | 0.56% | $35,821.23 | $645.2M | — |
| 40 | NGNE | Neurogene Inc. | Healthcare | 0.56% | $35,662.45 | $465.3M | — |
| 41 | NPCE | NeuroPace, Inc. | Healthcare | 0.55% | $34,614.49 | $420.1M | — |
| 42 | 4592 | Sanbio Company Limited | Healthcare | 0.54% | $34,570.03 | — | — |
| 43 | 2190 | Zylox-Tonbridge Med Tech Co | Healthcare | 0.54% | $34,188.95 | — | — |
| 44 | 7666 | METIS TECHBIO-P | Healthcare | 0.54% | $33,985.71 | — | — |
| 45 | CAPR | Capricor Therapeutics, Inc. | Healthcare | 0.50% | $31,756.41 | $390.1M | — |
| 46 | BNTC | Benitec Biopharma Inc. | Healthcare | 0.44% | $28,180.64 | $282.9M | — |
| 47 | 2172 | MicroPort NeuroTech Ltd | Healthcare | 0.42% | $26,611.87 | — | — |
| 48 | CLPT | ClearPoint Neuro, Inc. | Healthcare | 0.39% | $24,681.08 | $276.7M | — |
| 49 | ABEO | Abeona Therapeutics Inc. | Healthcare | 0.37% | $23,328.26 | $253.3M | — |
| 50 | VNDA | Vanda Pharmaceuticals Inc. | Healthcare | 0.36% | $22,756.64 | $243.7M | — |
| 51 | KYTX | Kyverna Therapeutics, Inc. | Healthcare | 0.35% | $22,153.27 | $350.7M | — |
| 52 | SANN | Santhera Pharmaceuticals Holding AG | Healthcare | 0.34% | $21,549.90 | — | — |
| 53 | NWRN | Newron Pharmaceuticals SpA | Healthcare | 0.27% | $17,421.57 | — | — |
| 54 | PEPG | PepGen Inc. | Healthcare | 0.27% | $16,919.82 | $179.8M | — |
| 55 | ALEC | Alector, Inc. | Healthcare | 0.23% | $14,468.22 | $205.4M | — |
| 56 | MOBI | Mobia Medical, Inc. | Healthcare | 0.21% | $13,540.93 | $269.3M | — |
| 57 | AVXL | Anavex Life Sciences Corp. | Healthcare | 0.20% | $12,670.81 | $121.4M | — |
| 58 | NGEN | NervGen Pharma Corp. | Healthcare | 0.19% | $12,245.27 | $171.0M | — |
| 59 | ABOS | Acumen Pharmaceuticals, Inc. | Healthcare | 0.19% | $12,213.52 | $122.2M | — |
| 60 | CAMP | CAMP4 Therapeutics Corporation | Healthcare | 0.19% | $12,111.89 | $198.9M | — |
| 61 | TRDA | Entrada Therapeutics, Inc. | Healthcare | 0.18% | $11,171.91 | $170.2M | — |
| 62 | LRMR | Larimar Therapeutics, Inc. | Healthcare | 0.18% | $11,127.45 | $206.2M | — |
| 63 | VYGR | Voyager Therapeutics, Inc. | Healthcare | 0.14% | $9,190.31 | $117.1M | — |
| 64 | MPLT | MapLight Therapeutics, Inc. | Healthcare | 0.14% | $9,012.47 | $427.9M | — |
| 65 | NERV | Minerva Neurosciences, Inc. | Healthcare | 0.14% | $8,879.09 | $112.2M | — |
| 66 | TNXP | Tonix Pharmaceuticals Holding Corp. | Healthcare | 0.13% | $8,396.39 | $103.6M | — |
| 67 | CGTX | Cognition Therapeutics, Inc. | Healthcare | 0.09% | $5,786.02 | $69.4M | — |
| 68 | NMRA | Neumora Therapeutics, Inc. | Healthcare | 0.05% | $2,940.64 | $89.0M | — |
Weights as a percentage of net assets. Value held = weight × net assets ($6.4M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
IBRN sector breakdown
Sum of the weights of the holdings in each sector.
IBRN top industries
IBRN overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| IWM | iShares Russell 2000 ETF | 2.0% | 46 of 1,962 | 0.19% |
| VTI | Vanguard Total Stock Market ETF | 0.2% | 43 of 2,941 | 0.03% |
| VXUS | Vanguard Total International Stock ETF | 0.1% | 6 of 8,035 | 0.05% |
| SPY | SPDR S&P 500 ETF | 0.1% | 1 of 502 | 0.09% |
| QQQ | Invesco QQQ ETF | 0.0% | 0 of 101 | 0.17% |
| DIA | SPDR Dow Jones Industrial Average ETF | 0.0% | 0 of 30 | 0.16% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the IBRN portfolio
iShares Neuroscience and Healthcare ETF holds 68 positions. The ten largest make up 42.1% of the fund and the top 50 96.5%, so it behaves like a portfolio of about 34 equally weighted stocks. The biggest positions are Biogen Inc. (5.86%), Alkermes plc (4.66%), Edgewise Therapeutics, Inc. (4.55%), Neurocrine Biosciences, Inc. (4.47%), PTC Therapeutics, Inc. (4.25%).
By sector, Healthcare is 100.0%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 24, 2026; positions change as the fund rebalances.
Related: IBRN chart, IBRN performance, IBRN dividends, IBRN overview.
IBRN holdings FAQ
How many holdings does IBRN have?
IBRN holds 68 positions as of October 24, 2026.
What are the top 10 holdings of IBRN?
The ten largest holdings are Biogen Inc. (5.86%), Alkermes plc (4.66%), Edgewise Therapeutics, Inc. (4.55%), Neurocrine Biosciences, Inc. (4.47%), PTC Therapeutics, Inc. (4.25%), argenx SE (4.02%), Scholar Rock Holding Corporation (3.65%), ACADIA Pharmaceuticals Inc. (3.58%), Dianthus Therapeutics, Inc. (3.58%), Supernus Pharmaceuticals, Inc. (3.45%). Together they are 42.1% of the fund.
What percentage of IBRN is Biogen Inc.?
Biogen Inc. is the largest holding at 5.86% of net assets, about $371,937.43 of the fund's $6.4M.
How concentrated is IBRN?
The top 10 holdings are 42.1% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) IBRN behaves like a portfolio of about 34 equally weighted stocks.